Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)

Novartis

Status: Completed

Conditions: Acute Myeloid Leukemia (AML)

Treatments: Drug: Midostaurin

Study type: Observational

Funder types: Industry

Identifiers

NCT05488613

CPKC412AFI02

Details and patient eligibility

About

This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.

Full description

Adult patients (18 years or older) with the inclusion diagnosis, AML (ICD-10 C92.0), between 1.1.2013 - 30.6.2020 were followed from the index date (first ever record of the inclusion diagnosis) until the end of follow-up (30.6.2020), or death. This study did not involve any contacts to patients.

The study inclusion period was changed from 1.1.2013 - 30.6.2020 specified in the protocol to 1.1.2016 - 30.6.2020 due to lack of medication data from pre-2016.

Enrollment: 81 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are diagnosed with acute myeloid leukemia (ICD-10 C92.0) during 1.1.2016-30.6.2020
• Adult (18 years or older) at the time of first diagnosis
• Health registry data is available and accessible
• Resident in the hospital district HUS at the time of index diagnosis

Exclusion criteria

• AML patients with no treatment information

Trial design

81 participants in 1 patient group

Midostaurin

Description:

Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.

Treatment:

Drug: Midostaurin